Cargando…

Pirtobrutinib results in reversible platelet dysfunction compared to ibrutinib and acalabrutinib

Detalles Bibliográficos
Autores principales:	Bye, Alexander P., Kriek, Neline, Sage, Tanya, Rawlings, Suzannah J., Prodger, Catherine, Kesavan, Murali, Lees, Charlotte, Booth, Stephen, Cowen, Louise G, Shefferd, Kirsty, Desborough, Michael J., Gibbins, Jonathan M., Eyre, Toby A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Fondazione Ferrata Storti 2022
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10153540/ https://www.ncbi.nlm.nih.gov/pubmed/36519322 http://dx.doi.org/10.3324/haematol.2022.281402

Ejemplares similares

Cobimetinib and trametinib inhibit platelet MEK but do not cause platelet dysfunction
por: Unsworth, Amanda J., et al.
Publicado: (2018)

RXR Ligands Negatively Regulate Thrombosis and Hemostasis
por: Unsworth, Amanda J., et al.
Publicado: (2017)

Protein Disulphide Isomerase and NADPH Oxidase 1 Cooperate to Control Platelet Function and Are Associated with Cardiometabolic Disease Risk Factors
por: Gaspar, Renato Simões, et al.
Publicado: (2021)

Differences and similarities in the effects of ibrutinib and acalabrutinib on platelet functions
por: Series, Jennifer, et al.
Publicado: (2019)

Farnesoid X Receptor and Liver X Receptor Ligands Initiate Formation of Coated Platelets
por: Unsworth, Amanda J., et al.
Publicado: (2017)

Distinct Effects of Ibrutinib and Acalabrutinib on Mouse Atrial and Sinoatrial Node Electrophysiology and Arrhythmogenesis
por: Tuomi, Jari M., et al.
Publicado: (2021)

Real-world comparative effectiveness of acalabrutinib and ibrutinib in patients with chronic lymphocytic leukemia
por: Roeker, Lindsey E., et al.
Publicado: (2023)

Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance
por: Naeem, Aishath, et al.
Publicado: (2022)

Cucurbitacins Elicit Anti-Platelet Activity via Perturbation of the Cytoskeleton and Integrin Function
por: Kriek, Neline, et al.
Publicado: (2022)

Clinical Trials of the BTK Inhibitors Ibrutinib and Acalabrutinib in Human Diseases Beyond B Cell Malignancies
por: Zhu, Sining, et al.
Publicado: (2021)

Multiparameter phenotyping of platelet reactivity for stratification of human cohorts
por: Dunster, Joanne L., et al.
Publicado: (2021)

Platelet factor XIII-A regulates platelet function and promotes clot retraction and stability
por: Mitchell, Joanne L., et al.
Publicado: (2023)

Multifaceted Immunomodulatory Effects of the BTK Inhibitors Ibrutinib and Acalabrutinib on Different Immune Cell Subsets – Beyond B Lymphocytes
por: Zhu, Sining, et al.
Publicado: (2021)

Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial
por: Byrd, John C., et al.
Publicado: (2021)

Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial
por: Seymour, John F., et al.
Publicado: (2023)

The potential of pirtobrutinib in multiple B-cell malignancies
por: Jensen, Jeffrey L., et al.
Publicado: (2022)

Fully automated platelet differential interference contrast image analysis via deep learning
por: Kempster, Carly, et al.
Publicado: (2022)

Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell Lymphoma
por: Wang, Michael L., et al.
Publicado: (2023)

Inhibition of Btk by Btk-specific concentrations of ibrutinib and acalabrutinib delays but does not block platelet aggregation mediated by glycoprotein VI
por: Nicolson, Phillip L.R., et al.
Publicado: (2018)

Antitumor Potency of an Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, Lisocabtagene Maraleucel in Combination With Ibrutinib or Acalabrutinib
por: Qin, Jim S., et al.
Publicado: (2020)

P633: UPDATED SAFETY AND EFFICACY RESULTS OF ZANUBRUTINIB IN PATIENTS WITH B-CELL MALIGNANCIES WHO ARE INTOLERANT OF IBRUTINIB AND/OR ACALABRUTINIB
por: Shadman, Mazyar, et al.
Publicado: (2023)

PPARγ agonists negatively regulate αIIbβ3 integrin outside‐in signaling and platelet function through up‐regulation of protein kinase A activity
por: Unsworth, A. J., et al.
Publicado: (2017)

P618: LONG-TERM SAFETY WITH ≥12 MONTHS OF PIRTOBRUTINIB IN RELAPSED/REFRACTORY (R/R) B-CELL MALIGNANCIES
por: Jurczak, Wojciech, et al.
Publicado: (2023)

Aberrant glycosylation of anti-SARS-CoV-2 spike IgG is a prothrombotic stimulus for platelets
por: Bye, Alexander P., et al.
Publicado: (2021)

Antiplatelet properties of Pim kinase inhibition are mediated through disruption of thromboxane A2 receptor signaling
por: Unsworth, Amanda J., et al.
Publicado: (2020)

Bruton’s Tyrosine Kinase Inhibitors Ibrutinib and Acalabrutinib Counteract Anthracycline Resistance in Cancer Cells Expressing AKR1C3
por: Morell, Anselm, et al.
Publicado: (2020)

BTK gatekeeper residue variation combined with cysteine 481 substitution causes super-resistance to irreversible inhibitors acalabrutinib, ibrutinib and zanubrutinib
por: Estupiñán, H. Yesid, et al.
Publicado: (2021)

Real-World Comparison of First-Line Treatment Adherence Between Single-Agent Ibrutinib and Acalabrutinib in Patients with Chronic Lymphocytic Leukemia
por: Lu, Xiaoxiao, et al.
Publicado: (2023)

P623: MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC) OF PIRTOBRUTINIB VS VENETOCLAX CONTINUOUS MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY CLL PREVIOUSLY TREATED WITH A COVALENT BTK INHIBITOR
por: Al-Sawaf, Othman, et al.
Publicado: (2023)

Front-Line Treatment of High Grade B Cell Non-Hodgkin Lymphoma
por: Kesavan, Murali, et al.
Publicado: (2019)

Pirtobrutinib: a new hope for patients with BTK inhibitor–refractory lymphoproliferative disorders
por: Thompson, Philip A., et al.
Publicado: (2023)

Preclinical characterization of pirtobrutinib, a highly selective, noncovalent (reversible) BTK inhibitor
por: Gomez, Eliana B., et al.
Publicado: (2023)

Acalabrutinib: Disseminated aspergillosis: case report
Publicado: (2022)

Cellular Therapy in High-Risk Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter Syndrome
por: Barbanti, Maria Chiara, et al.
Publicado: (2022)

The role of acalabrutinib in adults with chronic lymphocytic leukemia
por: Fakhri, Bita, et al.
Publicado: (2021)

NICE recommends acalabrutinib for chronic lymphocytic leukaemia
Publicado: (2021)

PB1861: ACALABRUTINIB IN THE TREATMENT OF RICHTER SYNDROME
por: Byalik, T., et al.
Publicado: (2022)

PB1948: ACALABRUTINIB IN THE TREATMENT OF RICHTER SYNDROME
por: Byalik, Tatyana, et al.
Publicado: (2023)

P1112: PATIENT-REPORTED OUTCOMES (PRO) AMONG PATIENTS WITH MANTLE CELL LYMPHOMA RECEIVING PIRTOBRUTINIB AFTER PRIOR COVALENT BTKI: INTERIM PRO ANALYSIS FROM THE BRUIN PHASE 1/2 STUDY
por: Cohen, Jonathon, et al.
Publicado: (2023)

Acalabrutinib for mantle cell lymphoma, chronic lymphocytic leukaemia
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_68nfl5kjv84e41eieovrk3hdlp